Biotech Voices

Biotech Voices is a collection of exclusive opinion editorials from some of the leading voices in biopharma on the biggest industry questions today. Our contributors are not paid for their opinions.

Have any questions or feedback, or think you have a voice that should be heard? Reach out to senior editors Kyle Blankenship and Amber Tong.

Biotech Voices

Biotech voices channel feed

The right to vote is fun­da­men­tal — a let­ter from biotech­nol­o­gy in­dus­try lead­ers

2 days ago
People

The con­tin­u­ing CRISPR patent saga

Last week

In­no­va­tion in the clin­ic is pick­ing up steam. How adap­tive de­signs could pave the road to per­son­al­ized med­i­cine

Last month

How we are stay­ing con­nect­ed when we’re apart

Last month

The path to NASH: un­der­stand­ing the role of se­vere obe­si­ty in a com­plex, mul­ti-sys­tem dis­ease

Last month

In­dus­try lead­ers need to speak out now more than ever

Last month

Why mu­cos­al im­mu­ni­ty may be re­quired to end the pan­dem­ic

2 months ago

How will the Biden ad­min­is­tra­tion af­fect fund­ing for life sci­ence re­search?

2 months ago

Re­vis­it­ing the 'cy­tokine stor­m' in ARDS; the painful wait for an­ti-in­flam­ma­to­ry drugs/tar­gets that solve Covid-19 deaths

2 months ago

We’re poised for a new era of med­ical ad­vances. A key step: un­der­stand­ing the mol­e­c­u­lar ma­chines that gov­ern health and dis­ease

2 months ago

Next-gen ther­a­pies are evolv­ing fast. The drug de­vel­op­ment mod­el needs to keep up

3 months ago

Bio­science in­dus­try stake­hold­er col­lab­o­ra­tion key to ad­dress­ing in­equal­i­ty

3 months ago

Biotech Voic­es: Coro­n­avirus will change biotech re­search with re­mote col­lab­o­ra­tions

10 months ago
Coronavirus

Two years in, Hong Kong’s biotech ex­per­i­ment has been val­i­dat­ed

11 months ago
Financing
China

Drug dis­cov­ery in the age of coro­n­avirus

Last year
Coronavirus

Bio­phar­ma has aban­doned an­tibi­ot­ic de­vel­op­ment. Here’s why we did, too.

Last year

Biotech boards bur­dened: Bridg­ing the suc­cess gap

Last year
Financing
Startups

Chi­na has be­come a CEO-lev­el pri­or­i­ty for multi­na­tion­al phar­ma­ceu­ti­cal com­pa­nies: the trend and the im­pli­ca­tions

Last year
China

Analy­sis: In most of the Big Phar­ma world, R&D spend­ing tow­ers over rev­enue from new drugs. Guess who beat the odds

Last year
R&D
Pharma

Brad Lon­car­'s AS­CO19 pre­view: 5 big ideas to watch for at the ul­ti­mate can­cer show of the year

Last year
R&D

The right mix mat­ters in bio­phar­ma lead­er­ship

Last year

Whale watch­ing: What a decade of change at Big Phar­ma taught us about cor­po­rate phe­no­types

Last year
Deals
Pharma

Phar­ma’s sum­mer of punk: Who's play­ing the hits — or tak­ing a hit — on the world in­no­va­tion tour

3 years ago
R&D

Phar­ma, we have a prob­lem: New drugs can't cov­er the cost of Big Phar­ma's fail­ures

3 years ago
R&D
12 Next page Last page